Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation

Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus

Waterfield, M. D., Scrace, G. T., Whittle, N., Stroobant, P., Johnsson, A., Wasteson, Å., Westermark, B., Heldin, C., Huang, J. S., & Deuel, T. F. (1983) · Nature · doi:10.1038/304035a0 · Cited by 1,616 · see citing works

Simian Sarcoma Virus onc Gene, v- sis , Is Derived from the Gene (or Genes) Encoding a Platelet-Derived Growth Factor

Doolittle, R. F., Hunkapiller, M. W., Hood, L., Devare, S. G., Robbins, K. C., Aaronson, S. A., & Antoniades, H. N. (1983) · Science · doi:10.1126/science.6304883 · Cited by 1,536 · see citing works

Growth factors from murine sarcoma virus-transformed cells.

Larco, J. E. D., & Todaro, G. J. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.8.4001 · Cited by 1,474 · see citing works

Recent developments in the cell biology of basic fibroblast growth factor.

Rifkin, D. B., & Moscatelli, D. (1989) · The Journal of Cell Biology · doi:10.1083/jcb.109.1.1 · Cited by 1,029 · see citing works

Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response.

Tannock, I. F., Gospodarowicz, M., Meakin, W., Panzarella, T., Stewart, L., & Rider, W. D. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.5.590 · Cited by 407 · see citing works

Suramin Protection of T Cells in Vitro Against Infectivity and Cytopathic Effect of HTLV-III

Mitsuya, H., Popovič, M., Yarchoan, R., Matsushita, S., Gallo, R. C., & Broder, S. E. (1984) · Science · doi:10.1126/science.6091268 · Cited by 393 · see citing works

Suramin inhibition of growth factor receptor binding and mitogenicity in AKR‐2B cells

Coffey, R. J., Leof, E. B., Shipley, G. D., & Moses, H. L. (1987) · Journal of Cellular Physiology · doi:10.1002/jcp.1041320120 · Cited by 379 · see citing works

Suramin: an anticancer drug with a unique mechanism of action.

Stein, C. A., Larocca, R. V., Thomas, R. V., McAtee, N., & Myers, C. E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.4.499 · Cited by 374 · see citing works

Suramin: A potent inhibitor of the reverse transcriptase of RNA tumor viruses

Clercq, E. D. (1979) · Cancer Letters · doi:10.1016/0304-3835(79)90017-x · Cited by 289 · see citing works

Suramin: With Special Reference to Onchocerciasis

Hawking, F. (1978) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60486-x · Cited by 285 · see citing works

Efficient reversion of simian sarcoma virus-transformation and inhibition of growth factor-induced mitogenesis by suramin.

Betsholtz, C., Johnsson, A., Heldin, C., & Westermark, B. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.17.6440 · Cited by 264 · see citing works

Suramin binds to platelet‐derived growth factor and inhibits its biological activity

Hosang, M. (1985) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240290310 · Cited by 256 · see citing works

EFFECTS OF SURAMIN ON HTLV-III/LAV INFECTION PRESENTING AS KAPOSI'S SARCOMA OR AIDS-RELATED COMPLEX: CLINICAL PHARMACOLOGY AND SUPPRESSION OF VIRUS REPLICATION IN VIVO

Broder, S. E., Collins, J., Markham, P., Redfield, R., Hoth, D., Groopman, J. E., Gallo, R. C., Yarchoan, R., Lane, H. C., Klecker, R. W., et al. (1985) · The Lancet · doi:10.1016/s0140-6736(85)90002-9 · Cited by 209 · see citing works

Platelet-derived growth factor receptors form a high affinity state in membrane preparations. Kinetics and affinity cross-linking studies.

Williams, L. T., Tremble, P., Lavin, M. F., & Sunday, M. E. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42987-5 · Cited by 202 · see citing works

Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?

Tannock, I. F. (1985) · Journal of Clinical Oncology · doi:10.1200/jco.1985.3.7.1013 · Cited by 170 · see citing works

EXPLORATION OF INDEPENDENCE

YDE, H. (1964) · The Lancet · doi:10.1016/s0140-6736(64)92701-1 · Cited by 169 · see citing works

Interference with normal phagosome-lysosome fusion in macrophages, using ingested yeast cells and suramin

Hart, P. D., & Young, M. R. (1975) · Nature · doi:10.1038/256047a0 · Cited by 162 · see citing works

Rapid turnover of the platelet-derived growth factor receptor in sis-transformed cells and reversal by suramin. Implications for the mechanism of autocrine transformation.

Huang, S. S., & Huang, J. S. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)37798-6 · Cited by 145 · see citing works

Transformation of NIH 3T3 cells with basic fibroblast growth factor or the hst/K-fgf oncogene causes downregulation of the fibroblast growth factor receptor: reversal of morphological transformation and restoration of receptor number by suramin.

Moscatelli, D., & Quarto, N. (1989) · The Journal of Cell Biology · doi:10.1083/jcb.109.5.2519 · Cited by 141 · see citing works

Clinical Pharmacokinetics of Suramin in Patients With HTLV‐III/LAV Infection

Collins, J. M., Klecker, R. W., Yarchoan, R., Lane, H. C., Fauci, A. S., Redfield, R. R., Broder, S. E., & Myers, C. E. (1986) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1986.tb02897.x · Cited by 137 · see citing works

Suramin‐induced polyneuropathy

Rocca, R. V. L., Meer, J., Gilliatt, R. W., Stein, C. A., Cassidy, J., Myers, C. E., & Dalakas, M. C. (1990) · Neurology · doi:10.1212/wnl.40.6.954 · Cited by 129 · see citing works

Suramin, an anti‐cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A

Hensey, C. E., Boscoboinik, D. O., & Azzi, A. (1989) · FEBS Letters · doi:10.1016/0014-5793(89)81639-4 · Cited by 104 · see citing works

Suramin Antiviral Therapy in the Acquired Immunodeficiency Syndrome

Levine, A. M., GILL, P. S., COHEN, J., HAWKINS, J. G., Formenti, S. C., AGUILAR, S., MEYER, P. R., KRAILO, M., PARKER, J., & RASHEED, S. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-105-1-32 · Cited by 103 · see citing works

Antiproliferative effects of suramin on lymphoid cells.

Spigelman, Z. S., Dowers, A., Kennedy, S., et al. (1987) · PubMed · Cited by 88 · see citing works

Suramin in Adrenal Cancer: Modulation of Steroid Hormone Production, Cytotoxicityin Vitro, and Clinical Antitumor Effect*

Rocca, R. V. L., Stein, C., Danesi, R., Jamis‐Dow, C., Weiss, G. H., & Myers, C. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-71-2-497 · Cited by 86 · see citing works

Experimental animal model for mucopolysaccharidosis: suramin-induced glycosaminoglycan and sphingolipid accumulation in the rat.

Constantopoulos, G., Rees, S. M., Cragg, B. G., Barranger, J. A., & Brady, R. O. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.6.3700 · Cited by 77 · see citing works

Circulating glycosaminoglycan anticoagulants associated with suramin treatment.

Horne, M. K., Stein, C. A., LaRocca, R. V., & Myers, C. E. (1988) · PubMed · doi:10.1182/blood.v71.2.273.273 · Cited by 76 · see citing works

Effect of Suramin on Human Prostate Cancer Cells in Vitro

Rocca, R. V. L., Danesi, R., Cooper, M. R., et al. (1991) · The Journal of Urology · doi:10.1016/s0022-5347(17)38351-9 · Cited by 72 · see citing works

Studies on suramin. 9. The action of the drug on some enzymes

Wills, E. D., & Wormall, A. (1950) · Biochemical Journal · doi:10.1042/bj0470158 · Cited by 71 · see citing works

Manual of Oncologic Therapeutics, 1989/1990

Markoe, A. M. (1990) · American Journal of Clinical Oncology · doi:10.1097/00000421-199002000-00027 · Cited by 59 · see citing works

Effects of suramin on complement, blood clotting, fibrinolysis and kinin formation

Eisen, V. D., & Loveday, C. (1973) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1973.tb08544.x · Cited by 41 · see citing works

Inhibition of vacuolar H+‐ATPases by fusidic acid and suramin

Moriyama, Y., & Nelson, N. (1988) · FEBS Letters · doi:10.1016/0014-5793(88)80121-2 · Cited by 40 · see citing works

Effects of suramin on the function and structure of the adrenal cortex in the cynomolgus monkey

FEUILLAN, P., RAFFELD, M., STEIN, C. A., LIPFORD, N., REHNQUIST, D., MEYERS, C. E., LAROCCA, R. V., & CHROUSOS, G. P. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-65-1-153 · Cited by 40 · see citing works

SIGNIFICANCE OF THE INCREASED FREQUENCY OF SELECTIVE CORTICAL NECROSIS OF ADRENAL

Wells, H. G. (1937) · JAMA · doi:10.1001/jama.1937.02780330018007 · Cited by 32 · see citing works

The Inhibition of Human Adrenal Steroidogenic Enzyme Activities by Suramin*

ASHBY, H., DiMattina, M., Linehan, W. M., et al. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-68-2-505 · Cited by 29 · see citing works

The effects of drugs on Onchocerca volvulus. 3. Trials of suramin at different dosages and a comparison of the brands Antrypol, Moranyl and Naganol.

Duke, B. O. L. (1968) · PubMed · Cited by 28 · see citing works

Effect of suramin on the activities of degradative enzymes of sphingolipids in rats.

Constantopoulos, G., Rees, S. M., Cragg, B. G., et al. (1981) · PubMed · Cited by 28 · see citing works

Effects of Suramin on the immune responses to sheep red blood cells in mice

Brandely, M., Lagrange, P. H., Hurtrel, B., et al. (1985) · Cellular Immunology · doi:10.1016/0008-8749(85)90134-0 · Cited by 14 · see citing works

The suramin-treated rat as a model of mucopolysaccharidosis

Rees, S. M., Constantopoulos, G., & Brady, R. O. (1986) · Virchows Archiv B Cell Pathology Including Molecular Pathology · doi:10.1007/bf02889967 · Cited by 13 · see citing works

Modulation by suramin of NK and monocytic cell-mediated cytotoxicity in human and murine cells

Zhang, H.-X., Sozzani, S., D’Alessandro, F., et al. (1988) · International Journal of Immunopharmacology · doi:10.1016/0192-0561(88)90023-9 · Cited by 7 · see citing works

Effects of Suramin on the immune responses to sheep red blood cells in mice

Motta, I., Brandely, M., Truffa‐Bachi, P., et al. (1985) · Cellular Immunology · doi:10.1016/0008-8749(85)90135-2 · Cited by 5 · see citing works

Adrenocortical carcinoma

Else, T., Kim, A. C., Sabolch, A., Raymond, V. M., Kandathil, A., Caoili, E. M., Jolly, S., Miller, B. S., Giordano, T. J., & Hammer, G. D. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1029 · Cited by 892 · see citing works

Suramin in adrenocortical cancer: limited efficacy and serious toxicity

Arlt, W., Reincke, M., Siekmann, L., WInkelmann, W., & Allolio, B. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02549.x · Cited by 36 · see citing works

The ability of suramin to block CD4-gp120 binding is reversed in the presence of albumin

Yao, X., Wainberg, M. A., Richard, M., et al. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.12.2636 · Cited by 6 · see citing works

Co-localization of suramin and serum albumin in lysosomes of suramin-treated human colon cancer cells

Baghdiguian, S., Boudier, J. A., Boudier, J., et al. (1996) · Cancer Letters · doi:10.1016/0304-3835(96)04132-8 · Cited by 3 · see citing works

Inhibitory effect of suramin on receptor binding and cytotoxic activity of tumor necrosis factor α

Grazioli, L., Alzani, R., Ciomei, M., et al. (1992) · International Journal of Immunopharmacology · doi:10.1016/0192-0561(92)90125-5 · Cited by 31 · see citing works

The uptake of the trypanocidal drug suramin in combination with low-density lipoproteins by Trypanosoma brucei and its possible mode of action

Vansterkenburg, E. L. M., Coppens, I., Wilting, J., et al. (1993) · Acta Tropica · doi:10.1016/0001-706x(93)90096-t · Cited by 84 · see citing works

Inhibition of angiogenesis by suramin.

Gagliardi, A., Hadd, H., & Collins, D. C. (1992) · PubMed · Cited by 92 · see citing works